SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shibmas was launched on the 9th Of December. The project is a meme token and gives homage to Shiba Inu the token. The token is a playful character who is bringing the Christmas spirit to token holders all around the world. We plan on getting many listings on various exchanges in the coming days. We have over 1000 holders in 24 hours and we aim on getting over 10000 holders within the next week and in the run up to Christmas

Shibmas

Shibmas ($SMAS) is gaining attention, with community members highlighting its potential for a breakout and strong chart setup, particularly within the Phantom Wallet ecosystem. Talk centers around the token's steady performance amid market hesitation and its potential for significant upward momentum. The community emphasizes its growing momentum and accessible entry point.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to optimism surrounding potential US-China trade deal developments, with discussions covering key trade issues and export controls. Community members are weighing the impact of this framework on the market, especially on futures, with many anticipating a bullish open. Concerns remain about whether this optimism is justified, the details of the deal, and its long-term impact.

WorldFinancial

WorldFinancial (WLFI) is trending as the community anticipates news and potential developments before the year's end, with some speculating on Wyoming's potential blockchain adoption.  Community members are actively discussing entry points and potential price movements, while others express strong opinions on the token's fundamentals and its connection to Donald Trump.  Broader conversations include potential utility through tokenized assets and a debit card, though some remain skeptical about its long-term value.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending following Novartis' ($NVS) acquisition agreement, which sent the stock soaring. The community is buzzing about the significant premium offered and potential windfalls for option holders and biotech investors. Some speculate about other potential buyout targets in the sector, while others discuss the deal's implications for Avidity's pipeline and spun-off cardiology programs.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the community anticipates potential catalysts such as a US/China trade deal and upcoming rate cuts, while also discussing its potential for a significant price surge. Bullish sentiment is fueled by institutions potentially positioning themselves, as well as anticipation of staking, while some traders point to technical indicators suggesting a breakout. Overall, the community is weighing positive news against ongoing market manipulation concerns.

Why Queen Kitty ($QKitty) Is The Meme Token You’ve Been Waiting For  Queen Kitty isn’t just another hype project—this is a real movement with substance and community power!  Why hold $QKitty? 😼 Real dev, real builds: No fake teams, no copy-paste code. Everything you see is made from scratch. 💧 Working Faucet: Free QKitty for the community. Want to know how? Just ask! 🏆 Big Buy Competition Bot: See top buyers live, fight for the throne, and win rewards! 🎮 Multi-token P2E game coming soon: Play and earn across Web, iOS, Android! 🐾 NFT collecting soon: Cutest collection in crypto, bringing perks and more ways to earn.  Queen Kitty means innovation, transparency, and real delivery for holders. Curious? Join the chat and ask anything!  $QKitty: By the community, for the community. To the moon, together! 🚀🐱

Queen Kitty

$QKITTY is trending as the community discusses its trading bot, which some claim generates daily interest. Some users express excitement for upcoming updates, while others share concerns, using the $BROKE tag. The coin is built on Solana, and there are mentions of potential integration with decentralized exchanges.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Token is trending as the community discusses its potential for real-world utility and adoption, particularly in light of developments around stablecoins and payment infrastructure. Some investors express frustration with the token's price action despite perceived positive news, while others remain optimistic about its long-term prospects, drawing comparisons to traditional payment systems' growth trajectories. Discussions also include speculation about market manipulation and the impact of regulatory clarity on AMP's future.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending as community members discuss its potential for significant growth, especially with its expanding role in bridging blockchain technology with gaming and AI. Bullish sentiment is fueled by the expectation of new exchange listings and the development of tokenized economies within virtual worlds. Some traders are taking profits while others believe it is a long term hold.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as positive news surrounding US-China trade talks sparks bullish sentiment, potentially averting tariffs and boosting crypto markets. The community is actively discussing potential price targets, with some anticipating a continued surge and others remaining cautious about short-term pullbacks. Many traders are watching key resistance levels, speculating about a breakout towards new all-time highs.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust Series 1 (QQQ) is trending as futures are up and the community anticipates a U.S.-China trade deal ahead of the Trump/Xi meeting, possibly signaling bullish momentum. Some investors express concerns about extreme market positioning and potential pullbacks, while others celebrate recent gains and dismiss bearish sentiment. Discussions also include upcoming Big Tech earnings, Fed rate cut expectations, and the impact of government shutdowns.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline

Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.

Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.

Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?

Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.

AbbVie Up More Than 30% in 6 Months: How to Play the Stock

AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.

The Zacks Analyst Blog Highlights AstraZeneca, RTX, Applied Materials, Park Aerospace and NetSol Technologies

Zacks spotlights AstraZeneca, RTX, and Applied Materials for strong performance and growth potential, while microcap names Park Aerospace and NetSol Technologies show niche momentum.

Top Research Reports for AstraZeneca, RTX & Applied Materials

AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.

Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.

Here's Why Astrazeneca (AZN) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

<p>AstraZeneca&nbsp;drew some retail investor attention early Monday after the pharma major reported that its cancer therapy Enhertu, developed with Daiichi Sankyo, achieved the highest pathologic complete response rate ever seen in a Phase 3 study for HER2-positive early breast cancer, showing both superior efficacy and a favorable safety profile compared with standard treatment.</p><h2 class="st-heading-2"><strong>Trial Results Show Record Response Rates</strong></h2><p>The DESTINY-Breast11 study, presented at the ESMO 2025 Presidential Symposium in Berlin, found that Enhertu followed by paclitaxel, trastuzumab and pertuzumab (THP) led to a pathologic complete response rate of 67.3%, compared with 56.3% for the standard anthracycline-based regimen (ddAC-THP). That marks an 11.2% absolute improvement, seen across both hormone receptor–positive and negative patients.</p><p>After surgery, over 81% of patients in the Enhertu group had no or minimal residual invasive cancer compared to 69% of patients treated with standard therapy. An early analysis of event-free survival showed a favorable trend with Enhertu, but the data are not mature.</p><h2 class="st-heading-2"><strong>Doctors See Potential New Standard Of Care</strong></h2><p>Nadia Harbeck, Director of the Breast Center at LMU University Hospital in Munich and the trial’s lead investigator, said the results suggest Enhertu could become a new standard of care in early, high-risk HER2-positive breast cancer.&nbsp;</p><p>AstraZeneca’s head of oncology R&amp;D Susan Galbraith added that the data show Enhertu “has the potential to transform treatment in the neoadjuvant setting.”</p><h2 class="st-heading-2"><strong>Safety Profile And Regulatory Outlook</strong></h2><p>Enhertu followed by THP was also better tolerated, with fewer severe side effects compared with standard therapy. Rates of Grade 3 or higher adverse events were 37.5% versus 55.8%, and heart-related side effects were lower. Interstitial lung disease rates were low and consistent across both groups.</p><p>The FDA is reviewing a supplemental Biologics License Application for Enhertu in this setting. Enhertu is being developed by AstraZeneca and Japan's Daiichi Sankyo.</p><h2 class="st-heading-2"><strong>Stocktwits Traders Turn Cautious</strong></h2><p>On Stocktwits, retail sentiment for AstraZeneca was ‘bearish’ amid ‘low’ message volume.</p><p><a href="https://stocktwits.com/symbol/AZN">AstraZeneca’s stock</a> has risen 32% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer

The Phase 3 trial showed Enhertu achieved a 67.3% complete response rate.

Equity

The Phase 3 trial showed Enhertu achieved a 67.3% complete response rate, outperforming standard therapy by more than 11 percentage points in high-risk HER2-positive early breast cancer.

DATROWAY (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option

Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual...

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group PLC. The company is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc - ADR

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$1.15	--	--	N/A
Q2 '25	$1.07	$1.09	1.02%	BEAT
Q1 '25	$1.12	$1.25	11.65%	BEAT
Q4 '24	$1.04	$1.04	0.03%	BEAT
Q3 '24	$1.02	$1.04	1.67%	BEAT

AZN
AstraZeneca PLC

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest AZN News

AZNAstraZeneca PLC